Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105 USD | -1.36% | -3.22% | -24.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's enterprise value to sales, at 3.78 times its current sales, is high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.57% | 16.96B | C+ | ||
+7.87% | 223B | B | ||
+11.83% | 195B | B- | ||
+18.87% | 144B | B- | ||
+30.03% | 111B | A- | ||
+2.32% | 65.19B | A- | ||
+14.15% | 53.02B | B+ | ||
+2.68% | 50.28B | B+ | ||
+6.60% | 44.15B | A | ||
+1.85% | 36.45B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ILMN Stock
- Ratings Illumina, Inc.